Replimune Group, Inc. (REPL)Healthcare | Biotechnology | Woburn, United States | NasdaqGS
15.50 USD
-0.10
(-0.641%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 15.45 -0.05 (-0.050%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:17 a.m. EDT
The investment case for Replimune is currently defined by a binary event risk rather than sustainable business fundamentals. The company is burning cash with negative free cash flow and a deteriorating balance sheet, while the stock has suffered a catastrophic 66% decline over the past seven years, reflecting the market's severe skepticism about its ability to execute. Although the FDA review acceptance offers a potential catalyst, the odds are stacked against the stock; the massive accumulation of put options by speculators suggests a consensus view that the upcoming decision could trigger further downside, not a rally. With no dividend to provide income and a history of multi-year declines, this is a speculative gamble on a clinical trial outcome rather than a sound investment vehicle. The short interest nearing 44% indicates heavy skepticism among retail investors, who may eventually force a squeeze, but the fundamental reality remains a distressed biotech play with no margin of safety. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.262108 |
| AutoTheta | 0.263312 |
| AutoETS | 0.263366 |
| MSTL | 0.312027 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 18% |
| H-stat | 4.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 105.992 |
| Market Cap | 1,460,404,352 |
| Forward P/E | -7.61 |
| Beta | 0.90 |
| Website | https://www.replimune.com |
As of Aug. 22, 2026, 5:17 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes 2.0, 3.0, 8.0) across multiple expirations, including significant volume spikes. Conversely, call activity is concentrated near the money or slightly out-of-the-money, with notable open interest walls at strikes significantly below the current price (e.g., 10.0, 13.0), suggesting a 'bear put ladder' strategy rather than a bullish breakout expectation. Implied volatility remains elevated on the downside strikes relative to the at-the-money level.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.6271186 |
| Address1 | 500 Unicorn Park Drive |
| Address2 | Suite 303, 3rd Floor |
| All Time High | 54.85 |
| All Time Low | 1.5 |
| Ask | 19.84 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 2,833,360 |
| Average Daily Volume3 Month | 4,979,992 |
| Average Volume | 4,979,992 |
| Average Volume10Days | 2,833,360 |
| Beta | 0.9 |
| Bid | 15.44 |
| Bid Size | 3 |
| Board Risk | 8 |
| Book Value | 1.258 |
| City | Woburn |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 15.5 |
| Current Ratio | 5.228 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 15.87 |
| Day Low | 15.4 |
| Debt To Equity | 105.992 |
| Display Name | Replimune |
| Earnings Call Timestamp End | 1,747,915,200 |
| Earnings Call Timestamp Start | 1,747,915,200 |
| Earnings Timestamp | 1,786,710,600 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -290,440,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.741 |
| Enterprise Value | 1,377,051,264 |
| Eps Current Year | -2.97584 |
| Eps Forward | -2.03808 |
| Eps Trailing Twelve Months | -3.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.8075 |
| Fifty Day Average Change | 3.6925 |
| Fifty Day Average Change Percent | 0.31272498 |
| Fifty Two Week Change Percent | 162.71185 |
| Fifty Two Week High | 16.15 |
| Fifty Two Week High Change | -0.6499996 |
| Fifty Two Week High Change Percent | -0.040247656 |
| Fifty Two Week Low | 1.5 |
| Fifty Two Week Low Change | 14.0 |
| Fifty Two Week Low Change Percent | 9.333333 |
| Fifty Two Week Range | 1.5 - 16.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,532,093,400,000 |
| Float Shares | 67,652,524 |
| Forward Eps | -2.03808 |
| Forward P E | -7.605197 |
| Free Cashflow | -171,672,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 465 |
| Fullday Change | -0.1 |
| Fullday Change Percent | -0.641028 |
| Fullday Price | 15.45 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.016490001 |
| Held Percent Institutions | 1.04191 |
| Implied Shares Outstanding | 94,219,634 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Long Business Summary | Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts. |
| Long Name | Replimune Group, Inc. |
| Market | us_market |
| Market Cap | 1,460,404,352 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_571664452 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -297,012,992 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 1,469,826,290 |
| Number Of Analyst Opinions | 6 |
| Open | 15.402 |
| Operating Cashflow | -279,056,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 781 222 9600 |
| Post Market Change | -0.05000019 |
| Post Market Change Percent | -0.3225819 |
| Post Market Price | 15.45 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 15.6 |
| Price Eps Current Year | -5.2086134 |
| Price Hint | 2 |
| Price To Book | 12.321144 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.085 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.75 |
| Region | US |
| Regular Market Change | -0.1 |
| Regular Market Change Percent | -0.641028 |
| Regular Market Day High | 15.87 |
| Regular Market Day Low | 15.4 |
| Regular Market Day Range | 15.4 - 15.87 |
| Regular Market Open | 15.402 |
| Regular Market Previous Close | 15.6 |
| Regular Market Price | 15.5 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 2,386,210 |
| Return On Assets | -0.51296 |
| Return On Equity | -1.34286 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 94,219,634 |
| Shares Percent Shares Out | 0.26389998 |
| Shares Short | 24,866,611 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 23,654,362 |
| Short Name | Replimune Group, Inc. |
| Short Percent Of Float | 0.43080002 |
| Short Ratio | 3.43 |
| Source Interval | 15 |
| State | MA |
| Symbol | REPL |
| Target High Price | 24.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 19.5 |
| Target Median Price | 19.5 |
| Total Cash | 195,328,000 |
| Total Cash Per Share | 2.073 |
| Total Debt | 111,975,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.432625 |
| Two Hundred Day Average Change | 7.067375 |
| Two Hundred Day Average Change Percent | 0.83809906 |
| Type Disp | Equity |
| Volume | 2,386,210 |
| Website | https://www.replimune.com |
| Zip | 1,801 |